Newly developed gel helps improve the effectiveness of immunotherapy for glioblastoma

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.

Related Keywords

China ,Hongwei ,Sichuan ,California ,United States ,Zhejiang ,Zhen Gu ,Fujian ,Francess Ligler ,Mostafa Yazdimamaghani ,Shawn Hingtgen ,Emily Henderson ,Los Angeles ,Seema Nandi ,Simon Khagi ,Alain Valdivia ,Barbara Savoldo ,Edikan Ogunnaike ,Shannah Hudson ,University Of California ,Lineberger Comprehensive Cancer Center ,School Of Medicine Department Microbiology ,Zhejiang University ,University Of North Carolina ,Immunology Program ,Study First Author ,Biomedical Engineer ,Gianpietro Dotti ,Medicine Department ,Ernesto Leon ,Glioblastoma ,Immunotherapy ,Ntigen ,Flood ,Rain ,Dancer ,Fell ,Chimeric Antigen Receptor ,Mmunology ,Alignant ,Fact ,Protein ,Eceptor ,Research ,Surgery ,Humor ,Hound ,